A joint study by Giunchan Ltd. and Konyang University College of Medicine discovered that GMK, a mushroom mycelium material, can inhibit and improve symptoms of Alzheimer's disease (AD). GMK works by preventing the buildup of dementia-linked beta-amyloid in neurons. With Alzheimer's being a major global concern, expected to affect over 130 million by 2050, this research offers hope for a more effective treatment. The findings were published in an international journal, and a related patent has been filed.